Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials
Journal of Investigative Medicine · 08.06.2026
DOI: 10.1177/10815589261460894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Investigative Medicine, online erschienen am 08.06.2026. Verfasst von Luis E Simental-Mendía und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Biomédica, Delegación Durango, Instituto Mexicano del Seguro Social, Durango, México. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Recently, it has been reported that dual agonists of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR) have important functions in regulating glucose metabolism and energy expenditure. However, the usefulness of these dual agonists for the treatment of type 2 diabetes remains unclear. This systematic review and meta-analysis of randomized controlled trials aimed to assess the impact of GLP-1/GCGR dual agonists on glycemic markers. The search process was performed in PubMed, Scopus, ClinicalTrials.gov, and Cochrane Library databases. Randomized controlled trials assessing the impact of GLP-1/GCGR agonists on glycemic parameters were included. The meta-analysis was performed with the random-effects model and the generic inverse variance method, and the leave-one-out method was used for the sensitivity analysis. The meta-analysis of 14 randomized controlled trials demonstrated that GLP-1/GCGR agonists significantly decrease fasting glucose (weighted mean difference (WMD): –0.79 mmol/l, 95% confidence interval (CI): –1.14, –0.45, p < 0.0001, I 2 = 92%) and glycated hemoglobin (HbA1c; WMD: –0.50%, 95% CI: –0.67, –0.32, p < 0.0001, I 2 = 93%). However, these dual agonists had no significant impact on insulin levels (WMD: –14.78 pmol/l, 95% CI: –35.89, 6.34, p = 0.17, I 2 = 87%). The subgroup analysis by treatment duration exhibited that GLP-1/GCGR agonists significantly reduced fasting glucose and HbA1c in randomized controlled trials ≤12 and >12 weeks, as well as insulin levels in those studies >12 weeks of treatment. In conclusion, the results of our meta-analysis indicated that GLP-1/GCGR dual agonists have a positive effect by decreasing fasting glucose and HbA1c concentrations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unidad de Investigación Biomédica, Delegación Durango, Instituto Mexicano del Seguro Social, Durango, México.
- Orthopedic Trauma Service, "Dr. José Eleuterio González" University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, México.
- Endocrinology Division, Hospital Universitario "Dr. José E. González," Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, México.
ORCID-Profile: Luis E Simental-Mendía, Mario Simental-Mendía, Paola Aguillón-Marín, Adriana Sánchez-García
Zitieren
APA
Simental-Mendía, L. E., Simental-Mendía, M., Aguillón-Marín, P., & Sánchez-García, A. (2026). Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials. Journal of Investigative Medicine. https://doi.org/10.1177/10815589261460894
Vancouver
Simental-Mendía LE, Simental-Mendía M, Aguillón-Marín P, Sánchez-García A. Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials. Journal of Investigative Medicine. 2026. doi:10.1177/10815589261460894
BibTeX
@article{SimentalMenda2026,
author = {Simental-Mendía, Luis E and Simental-Mendía, Mario and Aguillón-Marín, Paola and Sánchez-García, Adriana},
title = {Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials},
journal = {Journal of Investigative Medicine},
year = {2026},
doi = {10.1177/10815589261460894}
}
EUVIMED